Horizon Discovery Group plc, UK translational genomics company developing and supplying patient-relevant drug discovery and diagnostic research toolsand DefiniGEN Ltd, a leading provider of stem cell products and services, have entered into a collaboration to develop a range of unique, gene-engineered iPS (induced pluripotent stem)-based cell lines for use in research.
The partnership, formed to enable customers to exploit the power of genome editing in iPS cells, is made possible through Horizon’s deep expertise in gene editing, and DefiniGEN’s world-leading iPS cell-derived human cell production and metabolic disease modelling capabilities
Under the terms of the agreement, Horizon will perform genome engineering on the iPS cells, which will then be differentiated by DefiniGEN. Main focus is on generation of ten iPS-based cell lines for research in areas that currently lack high quality disease models.
Further resulting cell lines will be cultured, differentiated and quality controlled by DefiniGEN to ensure that scientists receive uniform cell populations suited to their experiments, alongside an isogenic control. The cell line reagents will be available through DefiniGEN and co-marketed by Horizon.
Subscribe to PharmaTutor News Alerts by Email >>
